Science Daily: Pharmacology News
DECEMBER 4, 2024
A new study sheds light on how long humans in the Americas have had relationships with the ancestors of today's dogs -- and asks an 'existential question': What is a dog?
Drug Target Review
DECEMBER 9, 2024
The 2024 Nobel Prize in Chemistry was awarded to Demis Hassabis and John Jumper from Google DeepMind for developing AlphaFold2, and to David Baker from the University of Washington for his work in computational protein design. These innovations have revolutionised the understanding of protein structures using artificial intelligence. Before AlphaFold, determining 3D protein structures was complex and time-consuming, and often required the use of experimental methods like X-ray crystallography an
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioPharma Drive: Drug Pricing
DECEMBER 4, 2024
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.
Drugs.com
DECEMBER 2, 2024
MONDAY, Dec. 2, 2024 -- A new study provides good evidence that the human papillomavirus (HPV) vaccine may be achieving its goal of slashing rates of cervical cancer.“We observed a … 62% drop in cervical cancer deaths over the last decade, likely du.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Chemical Biology and Drug Design
DECEMBER 20, 2024
The polypurine/polypyrimidine (pPu/pPy) tract, located in the proximal 36-bp region of the VEGF-A promoter(80 and 50), can switch between G-quadruplex and duplex structures, acting as a transcriptional inhibitor/activator between 85 and 50. Peptide ligands target and stabilise the VEGF G-quadruplex, thus lowering transcription and inhibiting angiogenesis.
Drug Patent Watch
DECEMBER 12, 2024
Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies. In this comprehensive guide, we’ll explore the intricacies of identifying such drugs and leveraging them for successful in-licensing opportunities.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Collaborative Drug
DECEMBER 6, 2024
We recently hosted an insightful webinar featuring the team from Congruence Therapeutics , who shared how they're using CDD Vault alongside their proprietary systems to manage complex drug discovery data. The impressive lineup of speakers included Maximilian Ebert (Executive Director of Computational Chemistry), Jeremy Dupaul-Chicoine (Associate Director of Biology), and Lee Fader (Vice President of Chemistry).
BioPharma Drive: Drug Pricing
DECEMBER 2, 2024
The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that has gripped the FDA and compounding pharmacies over the past few months.
Drugs.com
DECEMBER 3, 2024
TUESDAY, Dec. 3, 2024 -- A newly approved immunotherapy can help adults with a difficult-to-treat form of leukemia, clinical trial results show. Aucatzyl (obecabtagene autoleucel) worked on more than three-quarters (76%) of patients with B-cell.
Chemical Biology and Drug Design
DECEMBER 13, 2024
Tectorigenin could reduce the expression levels of inflammatory cytokines in both DBV-infected THP-1 cells and plasma samples of IFNAR / mice infected with DBV. ABSTRACT Severe fever with thrombocytopenia syndrome (SFTS) is a severe emerging infectious disease caused by Dabie bandavirus (DBV). Tectorigenin has been demonstrated to exert anti-inflammatory effect.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
DECEMBER 10, 2024
Patents play a crucial role in protecting intellectual property and fostering innovation. However, the increasing complexity of patent systems has given rise to a phenomenon known as “patent thickets.” These dense webs of overlapping patent rights can significantly impact innovation, market entry, and competition across various industries and countries.
Science Daily: Pharmacology News
DECEMBER 2, 2024
Researchers have linked a specific type of body fat to the abnormal proteins in the brain that are hallmarks of Alzheimer's disease up to 20 years before the earliest symptoms of dementia appear, according to a new study. The researchers emphasized that lifestyle modifications targeted at reducing this fat could influence the development of Alzheimer's disease.
Nvidia Developer: Drug Discovery
DECEMBER 3, 2024
Antibodies have become the most prevalent class of therapeutics, primarily due to their ability to target specific antigens, enabling them to treat a wide range. Antibodies have become the most prevalent class of therapeutics, primarily due to their ability to target specific antigens, enabling them to treat a wide range of diseases, from cancer to autoimmune disorders.
BioPharma Drive: Drug Pricing
DECEMBER 3, 2024
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to differentiated results, some analysts said.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drugs.com
DECEMBER 4, 2024
WEDNESDAY, Dec. 4, 2024 -- Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly."Given the increased interest around obesity medications, we conducted.
Chemical Biology and Drug Design
DECEMBER 13, 2024
The stabilization of the G-quadruplex region in the c-Myc and Bcl-2 promoter genes by voreloxin leads to the downregulation of c-Myc and Bcl-2 expression, resulting in apoptosis of leukemia cells. ABSTRACT Overexpression of c-Myc is a key factor in the development of leukemia and other malignancies, highlighting the urgent need for novel drugs to inhibit c-Myc protein levels.
Drug Patent Watch
DECEMBER 9, 2024
In the vast realm of pharmaceutical research and development, there’s a fascinating intersection between ancient wisdom and modern science. This intersection is where pharmacognosy meets drug patents, creating a unique landscape that shapes the future of medicine. But what exactly is pharmacognosy, and how does it relate to the complex world of drug patents?
Science Daily: Pharmacology News
DECEMBER 4, 2024
Some people bounce back from trauma, but others get caught in depressive loops that sap the joy from their lives.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
BioPharma Drive: Drug Pricing
DECEMBER 4, 2024
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide drug data.
Drugs.com
DECEMBER 16, 2024
MONDAY, Dec. 16, 2024 -- The established hormone therapy drug tamoxifen can significantly decrease the risk of cancer recurring in women with an early, low-risk form of breast cancer, a new study says. Women who took tamoxifen after undergoing a.
Chemical Biology and Drug Design
DECEMBER 12, 2024
The inhibitory profile of triaminopyrimidines was expanded and low nM IC 50 alky and aryl variants of CK-1-41 were discovered. Docking supported previous work indicating allosteric inhibition of caspase-1. Analogs with electrophilic warheads were created and inhibited caspase-1 in a partially reversible, time-dependent manner with experimental and docking results supporting allostery.
Drug Patent Watch
DECEMBER 3, 2024
In the ever-evolving landscape of pharmaceutical research and development, a revolutionary force is reshaping the way we approach drug discovery and repurposing. This force is none other than Artificial Intelligence (AI) and Machine Learning (ML).
Science Daily: Pharmacology News
DECEMBER 11, 2024
Is it possible to pass on the effects of malnutrition? A new animal study found that a protein-deficient diet in one generation created related health risks -- lower birth-weight, smaller kidneys -- in offspring that lasted four generations.
The ChEMBL-og
DECEMBER 12, 2024
Use your well-deserved Christmas holidays to spend time with your loved ones and explore the new release of ChEMBL 35! This fresh release comes with a wealth of new data sets and some new data sources as well. Examples include a total of 14 datasets deposited by by the ASAP ( AI-driven Structure-enabled Antiviral Platform) project, a new NTD data se t by Aberystwyth University on anti-schistosome activity, nine new chemical probe data sets, and seven new data sets for the Chemogenomic library of
BioPharma Drive: Drug Pricing
DECEMBER 2, 2024
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly 250-person study that should produce results next year.
Drugs.com
DECEMBER 4, 2024
WEDNESDAY, Dec. 4, 2024 -- The sugar known as fructose could be a kind of rocket fuel for cancer cells, and lowering fructose intake could be one way to fight the disease, new research suggests.Fructose is already ubiquitous in American diets, due.
Chemical Biology and Drug Design
DECEMBER 5, 2024
Three pancreatic cancer-related microarray datasets (GSE183795, GSE28735, and GSE62452) were integrated. Analysis of differentially expressed genes, WGCNA, and machine learning algorithms (LASSO, XGboost, and random forest) were combined to identify genes associated with the progression of pancreatic cancer. Natural drugs, including delphinidin, which target the core genes, tripartite motif containing 16 (TRIM16), and protein regulator of cytokinesis 1 (PRC1), were then identified.
Drug Patent Watch
DECEMBER 4, 2024
The pharmaceutical industry is undergoing a significant transformation with the advent of machine learning methods. These methods have the potential to revolutionize the drug discovery process by enhancing the efficiency and accuracy of identifying and developing new drug candidates.
Science Daily: Pharmacology News
DECEMBER 3, 2024
An average of four minutes of incidental vigorous physical activity a day could almost halve the risk of major cardiovascular events, such as heart attacks, for middle-aged women who do not engage in structured exercise, according to new research.
addgene Blog
DECEMBER 12, 2024
Prime Editing: Precise and Flexible CRISPR Editing Over 75,000 pathogenic genetic variants have been identified in humans and cataloged in the ClinVar database. Previously developed genome editing methods using nucleases and base editors have the potential to correct only a minority of those variants in most cell types. But prime editing, a CRISPR technique developed in David Lius lab in 2019, has added considerably more precision and flexibility to the CRISPR editing world.
BioPharma Drive: Drug Pricing
DECEMBER 4, 2024
The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier treatment regimen.
Drugs.com
DECEMBER 4, 2024
WEDNESDAY, Dec. 4, 2024 -- American seniors still pay more for health care than their counterparts in most other wealthy countries do, despite coverage by Medicare, a new study finds.They are also more likely to postpone or skip needed care because.
Expert insights. Personalized for you.
140 
Let's personalize your content